Spots Global Cancer Trial Database for A Study of HQP1351 in Patients With GIST or Other Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Official Title: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
Study ID: NCT03594422
Interventions
Study Description
Brief Summary: This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
Detailed Description: The primary objective of this phase 1 study is to determine the RP2D of HQP1351 in patients with GIST or other solid tumors. The secondary objective is to assess the safety, tolerability, PK and preliminary anti-tumor activities of HQP1351 in Patients With GIST or Other Solid Tumors.
Keywords
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sun-Yat Sen University Cancer Center, Guangzhou, Guangdong, China
Guangdong general hospital, Guangzhou, Guangdong, China
Henan cancer hospital, Zhengzhou, Henan, China
Union Hospital Tongji Medical College of Huazhong University of Science ang Technology, Wuhan, Hubei, China
Chinese PLA general hospital, Beijing, China, Beijing, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Contact Details
Name: Ruihua Xu, Professor
Affiliation: Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
